Current Medicinal Chemistry

Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK

Back

Cofactor Mimics as Selective Inhibitors of NAD-dependent Inosine Monophospate Dehydrogenase (IMPDH) - the Major Therapeutic Target

Author(s): Krzysztof W. Pankiewicz, Steven E. Patterson, Paul L. Black, Hiremagalur N. Jayaram, Dipesh Risal, Barry M. Goldstein, Lieven J. Stuyver and Raymond F. Schinazi

Affiliation: Pharmasset, Inc., 1860 Montreal Road, Tucker, Atlanta, GA 30084, USA.

Abstract:

IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broadspectrum antiviral agent, which in combination with interferon-α is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin) and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.

Keywords: inosine monophospate dehydrogenase, imp dehydrogenase, purine nucleotides, mycophenolic mofetil

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 11
ISSUE: 7
Page: [887 - 900]
Pages: 14
DOI: 10.2174/0929867043455648
Price: $58